Hao Luo

Dr. Hao Luo

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
DQDongjun Qin
Dongjun Qin
WWWeiwei Wang
Weiwei Wang
HLHu Lei
Hu Lei
HLHao Luo
Hao Luo
HCHaiyan Cai
Haiyan Cai
YWYINGLI WU
YINGLI WU
CDDO-Me reveals USP7 as a novel target in ovarian cancer cells CDDO-Me reveals USP7 as a novel target in ovarian cancer cells

13 March 2019 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
HLHao Luo
Hao Luo
BJBo Jing
Bo Jing
YXYu Xia
Yu Xia
YZYugen Zhang
Yugen Zhang
MHMeng Hu
Meng Hu
YWYINGLI WU
YINGLI WU
T-cell acute lymphoblastic leukemia (T-ALL) is a lymphoid malignancy caused by the oncogenic transformation of immature T-cell progenitors with poor outcomes. WP1130 has shown potent activity against a variety of cancer but whether WP1130 has anti-T-ALL activity is not clear. USP24, one target of WP1130, is one of the largest deubiquitinases and its detailed mechanism is poorly understood. The aim of this study was to explore whether WP1130 could suppress T-ALL and the role of USP24 in T-ALL. Molecular docking and cellular thermal shift assay were performed to determine whether and how WP1130 directly interact with USP24. Mitochondrial transmembrane potential assay was measured via Rhodamine 123 staining. USP24 was reactivated using the deactivated CRISPR-associated protein 9 (dCas9)-synergistic activation mediator (SAM) system. The in vivo results were examined by tumor xenografts in NOD-SCID mice. All statistical analyses were performed with the SPSS software package. WP1130 treatment decreased the viability and induces apoptosis of T-ALL cells both in vitro and in vivo. Furthermore, we demonstrated that knockdown of USP24 but not USP9X could significantly induce growth inhibition and apoptosis of T-ALL cells. Oncomine database showed that USP24 expression was upregulated in T-ALL samples and Kaplan–Meier results indicated that the USP24 was negatively but USP9X was positively associated with survival in T-ALL patients. Additionally, we proposed that WP1130 directly interacts with the activity site pocket of USP24 in T-ALL cells, which leads to the decrease of its substrates Mcl-1. Mechanistically, WP1130 induces apoptosis by accelerating the collapse of mitochondrial transmembrane potential via USP24-Mcl-1 axis. Altogether, using WP1130 as a chemical probe, we demonstrate that USP24 but not USP9X is a novel target in T-ALL cells. Moreover, we uncovered that WP1130 induces apoptosis by accelerating the collapse of mitochondrial transmembrane potential via USP24-Mcl-1 axis. These results provide that USP24-Mcl-1 axis may represent a novel strategy in the treatment of T-ALL and WP1130 is a promising lead compound for developing anti-T-ALL drugs.

24 September 2025 in Cell Death & Differentiation
Verified
Journal Article
Closed access
PDF file
HLHao Luo
Hao Luo
CZChujiao Zhu
Chujiao Zhu
YWYingying Wang
Yingying Wang
YDYidong Dai
Yidong Dai
PHPeng Hao
Peng Hao
YWYINGLI WU
YINGLI WU

31 March 2022 in Oncologie
Verified
Journal Article
Closed access
HLHao Luo
Hao Luo
YJYanjie Ji
Yanjie Ji
XGXinrong Gao
Xinrong Gao
XLXinying Liu
Xinying Liu
YWYunzhao Wu
Yunzhao Wu
YWYINGLI WU
YINGLI WU
The ubiquitin-proteasome system (UPS) is an important pathway for cellular protein degradation. The components of this pathway, including the proteasome, ubiquitinase, and deubiquitinase, are highly specialized and strictly regulated. The ubiquitin-specific protease 2 (USP2) belongs to the ubiquitin-specific proteases, a subgroup of deubiquitinating enzymes. USP2 plays essential roles in regulating cell survival, cell cycle, circadian rhythm, cell metabolism, inflammatory response, antiviral response, and metastasis by interacting with certain proteins such as Cyclin D1, PER1, CRY1, HDM2/p53, FASN, LDLR, TRAF6, TBK1, and TGFBR1-TGFBR2 complex. Elevation of USP2 has been observed in a variety of cancers, including glioma, testicular cancer, breast cancer, prostate cancer, and some inflammatory diseases. Moreover, USP2 also plays an important role in many non-neoplastic diseases. At present, there is no officially approved USP2 inhibitor in clinic. A few existing inhibitors targeting USP2 have shown certain effects in the treatment of colorectal cancer, but their mechanism of action and binding site information are not clear. Moreover, the efficacy and selection specificity need to be further optimized. The catalytic centers of USP family are relatively conserved, so the design of compounds targeting allosteric site is expected to improve the specificity and inhibitory activity. In this review, we summarize the latest advances of USP2 in its cellular function, related diseases, and small-molecule inhibitors targeting USP2.

21 February 2024 in Life Sciences
Verified
Journal Article
Closed access
XSXiaoyang Song
Xiaoyang Song
BXBoyu Xia
Boyu Xia
XGXinrong Gao
Xinrong Gao
XLXinying Liu
Xinying Liu
HLHongyuan Lv
Hongyuan Lv
HLHao Luo
Hao Luo

20 November 2025 in Science China Life Sciences
Verified
Journal Article
Closed access
PDF file
ZZZhenge Zhang
Zhenge Zhang
WDWanli Duan
Wanli Duan
YWYixiang Wang
Yixiang Wang
PHPeng Hao
Peng Hao
LCLinlin Chen
Linlin Chen
HLHao Luo
Hao Luo